Biotech 2050 Podcast cover image

David Meeker, CEO of Rhythm Pharmaceuticals, on Rare Disease Breakthroughs & Biotech’s Future

Biotech 2050 Podcast

00:00

Genzyme's Legacy in Rare Disease Biotech

This chapter explores how Genzyme crafted a successful business model for rare diseases by prioritizing distribution and product differentiation while cultivating trust and personal relationships in patient care. It highlights the impact of unique hiring practices and leadership strategies that emphasized risk-taking and culture maintenance, particularly after Genzyme's acquisition by Sanofi. The narrative further examines the broader implications of these practices in the biotech industry, especially regarding the evolving understanding of rare conditions like obesity.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app